BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 32988960)

  • 1. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
    Yap TA; Tan DSP; Terbuch A; Caldwell R; Guo C; Goh BC; Heong V; Haris NRM; Bashir S; Drew Y; Hong DS; Meric-Bernstam F; Wilkinson G; Hreiki J; Wengner AM; Bladt F; Schlicker A; Ludwig M; Zhou Y; Liu L; Bordia S; Plummer R; Lagkadinou E; de Bono JS
    Cancer Discov; 2021 Jan; 11(1):80-91. PubMed ID: 32988960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer.
    Shao J; Huang L; Lai W; Zou Y; Zhu Q
    Molecules; 2023 Jun; 28(11):. PubMed ID: 37298997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo.
    Bin H; Chen P; Wu M; Wang F; Lin G; Pan S; Liu J; Mu B; Nan J; Huang Q; Li L; Yang S
    Eur J Med Chem; 2022 Mar; 232():114187. PubMed ID: 35183872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATR Inhibition as an Attractive Therapeutic Resource against Cancer.
    Italiano A
    Cancer Discov; 2021 Jan; 11(1):14-16. PubMed ID: 34003779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR).
    Wang LW; Jiang S; Yuan YH; Duan J; Mao ND; Hui Z; Bai R; Xie T; Ye XY
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial Ovarian Carcinoma: Their Expression and Clinical Significance.
    Lee B; Lee HJ; Cho HY; Suh DH; Kim K; No JH; Kim H; Kim YB
    Anticancer Res; 2015 Jul; 35(7):3909-16. PubMed ID: 26124337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
    Gulliver C; Hoffmann R; Baillie GS
    Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase.
    Duan Y; Cheng H; Zhuang L; Xia J; Xu Y; Zhang R; Sun R; Lu T; Chen Y
    Eur J Med Chem; 2023 Jul; 255():115370. PubMed ID: 37130473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
    Yap TA; Fontana E; Lee EK; Spigel DR; Højgaard M; Lheureux S; Mettu NB; Carneiro BA; Carter L; Plummer R; Cote GM; Meric-Bernstam F; O'Connell J; Schonhoft JD; Wainszelbaum M; Fretland AJ; Manley P; Xu Y; Ulanet D; Rimkunas V; Zinda M; Koehler M; Silverman IM; Reis-Filho JS; Rosen E
    Nat Med; 2023 Jun; 29(6):1400-1411. PubMed ID: 37277454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ATR in Cancer Medicine.
    Salguero C; Valladolid C; Robinson HMR; Smith GCM; Yap TA
    Cancer Treat Res; 2023; 186():239-283. PubMed ID: 37978140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase.
    Alfayomy AM; Ashry R; Kansy AG; Sarnow AC; Erdmann F; Schmidt M; Krämer OH; Sippl W
    Eur J Med Chem; 2024 Mar; 267():116167. PubMed ID: 38308949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
    Yap TA; Tolcher AW; Plummer R; Mukker JK; Enderlin M; Hicking C; Grombacher T; Locatelli G; Szucs Z; Gounaris I; de Bono JS
    Clin Cancer Res; 2024 May; 30(10):2057-2067. PubMed ID: 38407317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
    Yap TA; Krebs MG; Postel-Vinay S; El-Khouiery A; Soria JC; Lopez J; Berges A; Cheung SYA; Irurzun-Arana I; Goldwin A; Felicetti B; Jones GN; Lau A; Frewer P; Pierce AJ; Clack G; Stephens C; Smith SA; Dean E; Hollingsworth SJ
    Clin Cancer Res; 2021 Oct; 27(19):5213-5224. PubMed ID: 34301752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ataxia Telangiectasia and Rad3-Related Activation by DNA Damage Mitigates Maladaptive Repair after Acute Kidney Injury.
    Bonventre JV
    Nephron; 2022; 146(3):274-277. PubMed ID: 34649246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-PKcs, ATM, and ATR Interplay Maintains Genome Integrity during Neurogenesis.
    Enriquez-Rios V; Dumitrache LC; Downing SM; Li Y; Brown EJ; Russell HR; McKinnon PJ
    J Neurosci; 2017 Jan; 37(4):893-905. PubMed ID: 28123024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.
    Waqar SN; Robinson C; Olszanski AJ; Spira A; Hackmaster M; Lucas L; Sponton L; Jin H; Hering U; Cronier D; Grinberg M; Seithel-Keuth A; Diaz-Padilla I; Berlin J
    Invest New Drugs; 2022 Jun; 40(3):596-605. PubMed ID: 35150356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative phosphoproteomics of the ataxia telangiectasia-mutated (ATM) and ataxia telangiectasia-mutated and rad3-related (ATR) dependent DNA damage response in Arabidopsis thaliana.
    Roitinger E; Hofer M; Köcher T; Pichler P; Novatchkova M; Yang J; Schlögelhofer P; Mechtler K
    Mol Cell Proteomics; 2015 Mar; 14(3):556-71. PubMed ID: 25561503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Adenovirus E4orf4 Protein Provides a Novel Mechanism for Inhibition of the DNA Damage Response.
    Brestovitsky A; Nebenzahl-Sharon K; Kechker P; Sharf R; Kleinberger T
    PLoS Pathog; 2016 Feb; 12(2):e1005420. PubMed ID: 26867009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
    Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.